Immunology and Microbiology
T Cell
100%
Cancer Cell
61%
CD47
44%
Cancer Immunotherapy
35%
CD20
34%
B Cell
33%
Bispecific Antibody
29%
TNF related apoptosis inducing ligand
27%
Ecalectin
26%
Monospecific Antibody
26%
Phagocytosis
25%
Macrophage
24%
Rituximab
24%
Tumor Necrosis Factor
23%
Cell Surface
22%
Antineoplastic Activity
22%
T Cell Receptor
21%
Cell Death
21%
Cytotoxic T-Cell
17%
Inflammatory Arthritis
17%
Calreticulin
16%
Cytotoxicity
15%
Immunotherapy
15%
Granulocyte
15%
Tumor Cell
14%
Immune Response
13%
Tumor Necrosis Factor Receptor
13%
Neutrophil
13%
Agonist
12%
CD8
12%
Cell Phagocytosis
11%
Tumor-Infiltrating Lymphocytes
11%
Myeloid
11%
Antigen Specificity
11%
CXCL16
10%
Atezolizumab
10%
Cetuximab
10%
Neutrophil Granulocyte
9%
Lymphocyte
9%
Autoimmunity
9%
Epidermal Growth Factor
9%
Tumor Immunity
9%
CD40 Ligand
9%
Surface Property
8%
Cell Line
8%
Cross Linking
8%
Endoplasmic reticulum
8%
Tumor Necrosis Factor Related Apoptosis Inducing Ligand
7%
Normal Human
7%
Antibody-Dependent Cell-Mediated Cytotoxicity
7%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
90%
Malignant Neoplasm
76%
Fusion Protein
74%
Elimination
34%
Tumor Necrosis Factor Related Apoptosis Inducing Ligand
27%
Epidermal Growth Factor Receptor
27%
Acute Myeloid Leukemia
22%
Nanoparticle
21%
Immunotherapy
20%
Rituximab
16%
Tumor Necrosis Factor
15%
Ovary Cancer
15%
Proteinase
15%
Bispecific Antibody
14%
Leukemia
13%
Tumor Necrosis Factor Related Apoptosis Inducing Ligand Receptor
12%
Single Chain Fragment Variable Antibody
11%
Melanoma
11%
Death Receptor
10%
Sodium Valproate
10%
Ecalectin
10%
Cytarabine
10%
Gemtuzumab Ozogamicin
10%
Calcium Carbonate
10%
Monoclonal Antibody
9%
Proteochondroitin Sulfate
9%
Receptor
8%
Drug Delivery System
8%
Trastuzumab
7%
CD40 Ligand
7%
T Cell Leukemia
7%
6 Diazo 5 Oxonorleucine
6%
Enzyme-Linked Immunosorbent Assay
6%
Side Effect
6%
Mouse
6%
Cytotoxicity
6%
Daratumumab
6%
Histone Deacetylase Inhibitor
6%
Clinical Trial
6%
Gamma Urogastrone
6%
Rheumatoid Arthritis
6%
Fas Ligand
6%
Controlled Release
6%
Epithelial Cell Adhesion Molecule
6%
Sodium Chloride
5%
Cytotoxicity
5%
Tissue Injury
5%
Glioblastoma
5%
Acute Lymphoblastic Leukemia
5%
Antibodies
5%
Medicine and Dentistry
T Cell
45%
Cancer Cell
41%
Fusion Protein
41%
Malignant Neoplasm
38%
Programmed Cell Death
35%
Antineoplastic Activity
30%
Neoplasm
29%
Tumor Necrosis Factor Related Apoptosis Inducing Ligand
24%
Cell Surface
23%
Calreticulin
16%
Cancer Immunotherapy
16%
Ovarian Cancer
16%
Rituximab
15%
Tumor Cell
15%
Proteinase
15%
Cancer Therapy
13%
Phagocytosis
13%
Bispecific Antibody
13%
Epidermal Growth Factor Receptor
12%
Diffuse Large B-Cell Lymphoma
11%
Target Cell
10%
Autophagy
10%
Macrophage
10%
Cell Death
9%
CD20
9%
Neutrophil
9%
In Vitro
8%
Endoplasmic reticulum
8%
Tumor Immunity
8%
Nodular Melanoma
7%
Autoimmunity
7%
Monoclonal Antibody
7%
Tumor Infiltrating Lymphocyte
7%
Lymphocyte
7%
Leukemia Cell
7%
Acute Myeloid Leukemia
7%
Single Chain Fragment Variable Antibody
6%
Tumor Necrosis Factor
6%
Overall Survival
6%
Granulocyte
6%
Antibody Dependent Cellular Cytotoxicity
6%
Cytotoxicity
6%
Immune Checkpoint Blockade
6%
Tumor Necrosis Factor Receptor
6%
Fas Ligand
6%
Immune Response
6%
CD8 Antigen
5%
Krukenberg Tumor
5%
Adult T-Cell Leukemia/Lymphoma
5%
Chimeric Antigen Receptor T-Cell
5%
